Wednesday, 04 October 2023 13:15

Takeover talk

Written by  Milking It

OPINION: Could Canterbury milk processor Synlait be a prime candidate for a takeover bid?

The listed company’s share price is hovering around $1.28/share.

Some analysts note that the projected fair value for Synlait Milk is NZ$2/share, based on 2 stage free cashflow to equity. The current price suggests Synlait is potentially 36% undervalued.

The 2023 annual results announced by Synlait didn’t really set the world alight. The feeling is that it’s crunch time for Synlait: either it shapes up or will be shipped out via a takeover bid.

More like this

Synlait is 'Burning Cash, Not Creating Value'

OPINION: Synlait's latest half-year result reveals a serious problem at the heart of the business: its core operations are no longer bringing in enough revenue to cover the cost of production.

Blunt CEO

OPINION: Synlait's woes show no sign of ending anytime soon.

Synlait, Nestlé Expand Eco-Focused Dairy Partnership in NZ

A partnership between Canterbury milk processor Synlait and the world's largest food producer, Nestlé, has been celebrated with a visit to a North Canterbury farm by a group including senior staff from Synlait, the Ravensdown subsidiary EcoPond, and Nestlé's Switzerland head office.

Featured

Penske NZ Appoints Stephen Kelly as General Manager

Penske Australia & New Zealand has appointed Stephen Kelly as the general manager of its Penske NZ operations, effective immediately In this role he will oversee all NZ branch operations, including energy solutions, mining, commercial vehicles, defence, marine, and rail, while continuing to be based at Penske’s Christchurch branch.

National

Machinery & Products

» Latest Print Issues Online

Milking It

Too Lenient

OPINION: Reckless action by Greenpeace in 2024 forced Fonterra to shut down a drying plant for four hours, costing the co-op…

Fossil Fuel Crusade

OPINION: The global crusade against fossil fuel is gaining momentum in some regions.

» Connect with Dairy News

» eNewsletter

Subscribe to our weekly newsletter